Compare · LLY vs PLYX
LLY vs PLYX
Side-by-side comparison of Eli Lilly and Company (LLY) and Polaryx Therapeutics Inc. (PLYX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PLYX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.06T, about 9673.9x PLYX ($109.2M).
- LLY has been more active in the news (13 items in the past 4 weeks vs 5 for PLYX).
- LLY has more recent analyst coverage (25 ratings vs 2 for PLYX).
- Company
- Eli Lilly and Company
- Polaryx Therapeutics Inc.
- Price
- $1121.18-2.41%
- $2.19-5.60%
- Market cap
- $1.06T
- $109.2M
- 1M return
- -
- -21.51%
- 1Y return
- -
- -93.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 5
- Recent ratings
- 25
- 2
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- EVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
Latest PLYX
- SEC Form DEFA14A filed by Polaryx Therapeutics Inc.
- SEC Form DEF 14A filed by Polaryx Therapeutics Inc.
- SEC Form S-8 filed by Polaryx Therapeutics Inc.
- Polaryx Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Polaryx Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events
- H.C. Wainwright initiated coverage on Polaryx Therapeutics with a new price target
- Chief Executive Officer Yang Alex Keun Mo bought $360,004 worth of shares (88,453 units at $4.07) (SEC Form 4)
- Polaryx Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
- Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards